Current advances in the development of therapies for neuromuscular disorders based on myostatin signalling, 3rd International Institute of Myology Workshop, Paris, September 12th, 2008

References 

1. Trollet C, Athanasopoulos T, Popplewell L, Malerba A, Dickson G. Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther. 2009;9:1–20
   • CrossRef
2. Magee TR, Artaza JN, Ferrini MG, et al. Myostatin short interfering hairpin RNA gene transfer increases skeletal muscle mass. J Gene Med. 2006;8:1171–1181
   • MEDLINE
   • CrossRef
3. Qiao C, Li J, Zheng H, et al. Hydrodynamic limb vein injection of AAV8 canine myostatin propeptide gene in normal dogs enhances muscle growth. Hum Gene Ther. 2009;20:1–10
   • CrossRef
4. Amthor H, Otto A, Vulin A, et al. Muscle hypertrophy driven by myostatin blockade does not require stem/precursor-cell activity. Proc Natl Acad Sci USA. 2009;106:7479–7484
5. Wolfman NM, McPherron AC, Pappano WN, et al. Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA. 2003;100:15842–15846
6. Lee SJ. Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS ONE. 2008;3:e1628
   • CrossRef
7. Lee SJ. Quadrupling muscle mass in mice by targeting TGF-beta signaling pathways. PLoS ONE. 2007;2:e789
   • CrossRef
8. Foster K, Graham IR, Otto A, et al. Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle. Rejuvenation Res. 2009;12:85–94
   • CrossRef
9. Amthor H, Macharia R, Navarrete R, et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci USA. 2007;104:1835–1840